Natera (NASDAQ:NTRA) Upgraded at BidaskClub

BidaskClub upgraded shares of Natera (NASDAQ:NTRA) from a buy rating to a strong-buy rating in a research note published on Thursday, BidAskClub reports.

Other equities research analysts have also recently issued research reports about the stock. Canaccord Genuity reaffirmed a buy rating and issued a $38.00 price target on shares of Natera in a research report on Wednesday, September 11th. Piper Jaffray Companies reaffirmed a buy rating on shares of Natera in a research report on Thursday, August 22nd. Craig Hallum upped their price target on shares of Natera from $29.00 to $37.00 and gave the stock a buy rating in a research report on Thursday, August 8th. Finally, Zacks Investment Research raised shares of Natera from a sell rating to a hold rating in a research report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $32.57.

Shares of NTRA opened at $33.72 on Thursday. The company has a 50 day moving average price of $30.90 and a 200-day moving average price of $24.42. Natera has a fifty-two week low of $11.08 and a fifty-two week high of $34.53. The stock has a market capitalization of $2.35 billion, a PE ratio of -15.68 and a beta of 1.43. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.42 and a current ratio of 2.54.



Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Wednesday, August 7th. The medical research company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.09. Natera had a negative net margin of 46.78% and a negative return on equity of 273.92%. The firm had revenue of $74.36 million during the quarter, compared to analysts’ expectations of $66.77 million. During the same quarter in the prior year, the company earned ($0.62) EPS. The company’s revenue was up 17.9% compared to the same quarter last year. Equities research analysts forecast that Natera will post -2.1 EPS for the current year.

In related news, CEO Steven Leonard Chapman sold 1,155 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $29.50, for a total transaction of $34,072.50. Following the completion of the sale, the chief executive officer now owns 4,525 shares of the company’s stock, valued at $133,487.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Michael Burkes Brophy sold 3,484 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $32.97, for a total transaction of $114,867.48. Following the sale, the chief financial officer now directly owns 15,362 shares of the company’s stock, valued at approximately $506,485.14. The disclosure for this sale can be found here. Insiders have sold 401,477 shares of company stock valued at $12,647,340 in the last three months. 9.29% of the stock is currently owned by corporate insiders.

Large investors have recently bought and sold shares of the stock. Focused Wealth Management Inc purchased a new stake in Natera during the second quarter valued at approximately $83,000. US Bancorp DE lifted its position in Natera by 575.2% during the second quarter. US Bancorp DE now owns 3,099 shares of the medical research company’s stock valued at $86,000 after acquiring an additional 2,640 shares during the last quarter. Bank of Montreal Can acquired a new position in Natera during the 2nd quarter valued at approximately $129,000. BNP Paribas Arbitrage SA increased its stake in Natera by 827.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,899 shares of the medical research company’s stock valued at $163,000 after purchasing an additional 7,047 shares in the last quarter. Finally, United Services Automobile Association acquired a new position in Natera during the 2nd quarter valued at approximately $242,000. 94.95% of the stock is owned by institutional investors.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Read More: What is the Coverage Ratio?

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.